The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases
- PMID: 21736545
- DOI: 10.2174/138161211797052484
The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases
Abstract
Glycogen synthase kinase (GSK-3) is a key enzyme in multiple cell processes. Since many pharmacological compounds that have effects on common metabolic pathways may have uses in many different diseases, we review here the possible involvement of glycogen synthase kinase 3 in diabetes, cancer and CNS diseases. Moreover, diabetes has recently been strongly linked to CNS diseases such as schizophrenia and bipolar illness. GSK-3 is both directly and indirectly inhibited by lithium, a key compound for treatment of bipolar disorder. Several antipsychotic drugs also affect the GSK-3 mediated pathways and postmortem study of brain in schizophrenia led to reports of alterations of GSK-3 activity or mRNA message. However, other reports are contradictory. Development of GSK-3 inhibitors for CNS diseases is complicated by the importance of GSK-3 in glucose metabolism and pancreas function and the possible effect of GSK-3 inhibition to be oncogenic. Further development of GSK-3 inhibitors for clinical trials should be approached with caution.
Similar articles
-
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.Eur J Med Chem. 2017 Jan 5;125:464-477. doi: 10.1016/j.ejmech.2016.09.058. Epub 2016 Sep 20. Eur J Med Chem. 2017. PMID: 27689729 Review.
-
Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.IUBMB Life. 2015 Dec;67(12):914-22. doi: 10.1002/iub.1454. Epub 2015 Nov 24. IUBMB Life. 2015. PMID: 26600003 Review.
-
Substrate competitive GSK-3 inhibitors - strategy and implications.Biochim Biophys Acta. 2010 Mar;1804(3):598-603. doi: 10.1016/j.bbapap.2009.09.010. Epub 2009 Sep 18. Biochim Biophys Acta. 2010. PMID: 19770076 Review.
-
[A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].Yao Xue Xue Bao. 2007 Dec;42(12):1227-31. Yao Xue Xue Bao. 2007. PMID: 18338632 Review. Chinese.
-
Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs.Med Res Rev. 2008 Sep;28(5):773-96. doi: 10.1002/med.20119. Med Res Rev. 2008. PMID: 18271054 Review.
Cited by
-
New insights into the role of GSK-3β in the brain: from neurodegenerative disease to tumorigenesis.PeerJ. 2023 Dec 12;11:e16635. doi: 10.7717/peerj.16635. eCollection 2023. PeerJ. 2023. PMID: 38107562 Free PMC article. Review.
-
MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma.Curr Issues Mol Biol. 2023 Sep 11;45(9):7432-7448. doi: 10.3390/cimb45090470. Curr Issues Mol Biol. 2023. PMID: 37754254 Free PMC article.
-
Glycogen Synthase Kinase-3β, NLRP3 Inflammasome, and Alzheimer's Disease.Curr Med Sci. 2023 Oct;43(5):847-854. doi: 10.1007/s11596-023-2788-4. Epub 2023 Sep 18. Curr Med Sci. 2023. PMID: 37721665
-
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?Int J Mol Sci. 2023 Apr 19;24(8):7541. doi: 10.3390/ijms24087541. Int J Mol Sci. 2023. PMID: 37108703 Free PMC article. Review.
-
Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors.RSC Adv. 2023 Apr 11;13(17):11278-11290. doi: 10.1039/d3ra01145c. eCollection 2023 Apr 11. RSC Adv. 2023. PMID: 37057264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
